Last reviewed · How we verify
Definity Suspension for Injection
Definity Suspension for Injection is a microbubble ultrasound contrast agent that enhances the visualization of cardiac structures and function.
Definity Suspension for Injection is a microbubble ultrasound contrast agent that enhances the visualization of cardiac structures and function. Used for Echocardiography enhancement, Cardiac function assessment.
At a glance
| Generic name | Definity Suspension for Injection |
|---|---|
| Also known as | Perflutren Lipid Microsphere, Microbubbles, DEFINITY |
| Sponsor | Sunnybrook Health Sciences Centre |
| Drug class | Ultrasound contrast agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
It works by producing a large number of microbubbles that are stable in the bloodstream and can be visualized with ultrasound. This allows for improved imaging of the heart and its blood vessels, which can be particularly useful in diagnosing and monitoring conditions such as coronary artery disease and cardiomyopathy.
Approved indications
- Echocardiography enhancement
- Cardiac function assessment
Common side effects
- Allergic reactions
- Hypersensitivity reactions
Key clinical trials
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer (PHASE1)
- A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography (PHASE1, PHASE2)
- Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) (PHASE1)
- Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy (PHASE1)
- Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography (PHASE3)
- Multi-organ Transit Time Acquisition Using Contrast Ultrasound
- MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer (PHASE1)
- Pancreas Ultrasound Imaging in type1 Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: